BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 183198)

  • 21. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
    Todman DH; Oliver WA; Edwards RL
    Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of bromocriptine in the treatment of Parkinson's disease.
    Stern GM; Lees AJ; Shaw KM; Lander CM
    Adv Biochem Psychopharmacol; 1980; 23():267-70. PubMed ID: 7395617
    [No Abstract]   [Full Text] [Related]  

  • 23. Patients sought for New Zealand multi-centre Parkinson's disease trial.
    Wallis WE
    N Z Med J; 1987 Jan; 100(816):33. PubMed ID: 3543760
    [No Abstract]   [Full Text] [Related]  

  • 24. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term use of dopamine agonists in Parkinson's disease.
    Jankovic J
    Clin Neuropharmacol; 1985; 8(2):131-40. PubMed ID: 3891082
    [No Abstract]   [Full Text] [Related]  

  • 27. Bromocriptine in Parkinson's disease.
    Stern G; Lees A
    Br J Hosp Med; 1978 Dec; 20(6):666-70. PubMed ID: 743580
    [No Abstract]   [Full Text] [Related]  

  • 28. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
    Frattola L; Albizzati MG; Spano PF; Trabucchi M
    Nouv Presse Med; 1976 Aug 28-Sep 4; 5(28):1761. PubMed ID: 958891
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism.
    Kartzinel R; Shoulson I; Calne DB
    Neurology; 1976 Jun; 26(6 PT 1):511-3. PubMed ID: 778655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bromocriptine and Parkinson's disease: initial results].
    Petit H; Destee A
    Lille Med; 1977; 22(6):362-5. PubMed ID: 578286
    [No Abstract]   [Full Text] [Related]  

  • 32. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
    Wallis WE
    Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further experiences with low doses of bromocriptine in Parkinson's disease.
    Fahn S; Côté LJ; Barrett RE; Snider SR
    Adv Biochem Psychopharmacol; 1980; 23():255-60. PubMed ID: 7395615
    [No Abstract]   [Full Text] [Related]  

  • 34. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical studies with bromocriptine in idiopathic parkinsonism.
    Teychenne PF; Kartzinel R; Perlow M; Pfeiffer R; Calne DB
    Trans Am Neurol Assoc; 1976; 101():302-4. PubMed ID: 1037483
    [No Abstract]   [Full Text] [Related]  

  • 38. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 39. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of bromocriptine in the treatment of Parkinson's disease.
    Mackenzie RA; Lance JW
    Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.